OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
g48831msi014.gif
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial - The Lancet Oncology
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without
![PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d8a6a7200a9b92c47e5ad3f2c4468f771fe2cb38/4-Figure2-1.png "PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar")
PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar
Current Oncology | Free Full-Text | Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆ - ScienceDirect
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial - ScienceDirect
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
NOVA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial - The Lancet Oncology
Tesaro begins phase III trial of niraparib for treatment of ovarian cancer – All About Drugs
PARP inhibition in breast cancer: progress made and future hopes | npj Breast Cancer
Tesaro Announces U.S. Fda Approval Of Zejula™ (Niraparib) Ovarian Cancer
Oncology Grand Rounds: Part 3 — PARP Inhibitors in Ovarian Cancer | Research To Practice
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | SpringerLink
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
SGO 2023: Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer
Niraparib - Zejula als onderhoudsbehandeling bij gevorderde eierstokkanker geeft een veel langere progressievrije overleving bij zowel patiënten met BRCA-gemuteerde eierstokkanker als bij niet BRCA-gemuteerd
